All News

Convention1.jpg

EULAR 2023: Featured Industry Presentations

Jack Cush, MD

EULAR 2023 opens tomorrow, Wednesday May 31st, with hundreds of novel presentations and pivotal clinical trials, many being featured industry sponsored clinical trials and research on their novel agents. Below is a collection of the featured abstracts, and presentation times from EULAR

Read Article
brain,pain,perception,cns

Orbitofrontal Cortex Implants to Assess Chronic Pain

Jack Cush, MD

Nature Neuroscience reports a novel approach to assessing chronic neuropathic pain - intracranial electrodes in the anterior cingulate cortex and orbitofrontal cortex (OFC) to map chronic pain signaling. 

Read Article
RheumNow Podcast square

3-4-5 Rule (5.26.2023)

Jack Cush, MD

Dr. Jack Cush reviews more than a dozen news, journal articles and RNL highlights from this past week on RheumNow.com.

Read Article
ANCA, vasculitis, test

International Consensus on ANCA-Associated Vasculitis with Glomerulonephritis

Jack Cush, MD

Nephrology Dialysis Transplantation has published an overview of the management of anti-neutrophil cytoplasmic antibody associated vasculitis with glomerulonephritis based on several international guidelines, including those frorm the ACR 2021, EULAR 2022 and KDIGO 2021 (Kidney Disease: Improving

Read Article
SI AS SpA ACR

ICYMI: Spondyloarthritis Innovations

Robert Chao, MD

The second day of RheumNow Live 2023 held in March ended with a focus on axial spondyloarthritis, especially on the evaluation of the definition of the disease, the inheritance of it, and of course the treatment of it.

Read Article
RheumNow Podcast square

Allergic Drug-Induced Arthritis (5.19.2023)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.  This week we delve into some odd associations, repeat drug warnings and the consequences of antirheumatic therapies.

Read Article
PSS.scleroderma.arthritis.contractures

Juvenile and Adult-onset Scleroderma Differ

Jack Cush, MD

A retrospecitve cohort comparision of juvenile (jSSc) and adult-onset (aSSc) systemic sclerosis (SSc) are both rare but present differently.  

Read Article
Researchers@of tomorrow. Winners of EULAR basic and epi and clinical abstract awards - young leaders! ⁦@RheumNow⁩ #EULAR2023 ⁦@eular_org⁩ https://t.co/VsV5aQpxjs
Janet Pope Janetbirdope ( View Tweet)
Save the date! We'll be tuning in live from Milan for EULAR '23. Count on us for: -KOL perspective videos -Clinical Trial Highlights -Daily Faculty Recaps -Live Streaming and more! https://t.co/9uKnDTynfk
Dr. John Cush RheumNow ( View Tweet)
Dr. Anisha Dua on Imaging in PMR: - US of shoulders to eval for bursitis can increase specificity - MRI better for pelvic girdle, but expensive - Consider PET if lack of response to steroids, r/o malignancy #RNL2023 @RheumNow https://t.co/tjhGlJPDWZ https://t.co/9h1FwfM0CP

Links:

Dr. John Cush RheumNow ( View Tweet)
Dr. Langford's take home for GPA. Remember to consider disease severity (will determine tx,) maintenance tx, and non-medical management including vaccination options for pts. #RNL2023 @RheumNow https://t.co/R6nrz7YXZr https://t.co/UVY0jDUGJ2

Links:

Dr. John Cush RheumNow ( View Tweet)
Avacopan in GPA - non-inferior to prednisone for induction remission - received FDA approval for treatment of severe active GPA in combo with standard therapy and steroids - should be used in newly diagnosed active or relapsing disease @rheumnow #RNL2023 https://t.co/My6M5MGBl1 https://t.co/0aPFUeE55Q

Links:

Dr. John Cush RheumNow ( View Tweet)
Dr. Langford #RNL2023 When to use CYC over RTX for severe GPA induction? - Severe disease with RTX intolerance - Worsening disease despite RTX - RGPN Cr > 4.0, mechanical ventilation? (these were excluded from RAVE trial) @RheumNow https://t.co/AnSAnGP6Oa https://t.co/iHF6tiFvj2

Links:

Dr. John Cush RheumNow ( View Tweet)
"Highest pre-test probability for GCA is actually: 1) Limb claudication 2) Jaw claudication #RNL2023 @RheumNow https://t.co/Ed52fIcVaI" https://t.co/dA1FlCEU3i

Links:

Dr. John Cush RheumNow ( View Tweet)
GCA biopsy: When and How Early is best, rec'd in first 2 weeks. Findings can be present at 8 weeks but be less prominent @anisha_dua rec's unilateral imaging in most pts, especially w scalp tenderness on one side >1 cm length #RNL2023 @RheumNow https://t.co/Pn25Qt0WL4 https://t.co/5qROaTbD2w

Links:

Dr. John Cush RheumNow ( View Tweet)
Dr. Spiera's approach to PMR treatment - prefers methylprednisolone - rapid taper over 16 weeks - consider GC sparing therapy (MTX, IL-6i) @Rheumnow #RNL2023 https://t.co/LR9e0aXkeN https://t.co/qXUBkz5vfe

Links:

Dr. John Cush RheumNow ( View Tweet)
Conaghan shares unpublished data from PROMOTE study at #RNL2023 Early data shows MTX benefits pain in patients w/ OA, particularly more metabolically active. Looking forward to more data on this-- https://t.co/Zfh7CbqvPi https://t.co/kIYKRFtUX2

Links:

Dr. John Cush RheumNow ( View Tweet)
DMARDs/TNF for PMR: MTX- initial benefit, but no 5 year steroid sparing effect Infliximab - no benefit Lef - some benefit in case series Robert Spiera #RNL2023 @RheumNow https://t.co/d7BpmxFfct https://t.co/jLJDPuMtD3

Links:

Dr. John Cush RheumNow ( View Tweet)
#RNL2023 Rob Spiera: I often use aspirin a day, especially if cranial complications and no contra-indications" No prospective studies, 2 large retrospective studies suggesting benefit @RheumNow https://t.co/V8C43LN5wl https://t.co/2focIzWhPP

Links:

Dr. John Cush RheumNow ( View Tweet)
One in Ten is Bad! This week on the Podcast Dr. Jack Cush reviews the news and journal articles, including the risks of dying, developing RA or autoimmune disease! https://t.co/5SXPotfhs0 https://t.co/jXwsWoltsy

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×